- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Oppenheimer raises Tyra Biosciences stock price target to $36 on market potential | 3 | Investing.com | ||
| 22.08. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08. | Achondroplasie-Studie: Tyra Biosciences behandelt erstes Kind mit Dabogratinib | 4 | Investing.com Deutsch | ||
| 21.08. | Tyra Biosciences doses first child in achondroplasia treatment trial | 1 | Investing.com | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.08. | Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia | 112 | PR Newswire | -Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-
-Initial results from safety sentinel cohort expected in 2H... ► Artikel lesen | |
| 14.08. | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights | 591 | PR Newswire | - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3... ► Artikel lesen | |
| 30.06. | Tyra Biosciences beginnt mit Dosierung in Phase-2-Studie für TYRA-300 bei Blasenkrebs | 1 | Investing.com Deutsch | ||
| 30.06. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) | 261 | PR Newswire | -TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC-
-Initial 3-month complete response (CR) data expected to be... ► Artikel lesen | |
| 29.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Piper Sandler raises Tyra Biosciences stock target to $33 | 1 | Investing.com | ||
| 08.05. | Tyra Biosciences GAAP EPS of -$0.47 | 1 | Seeking Alpha | ||
| 08.05. | Tyra Biosciences files $500M mixed securities shelf | 4 | Seeking Alpha | ||
| 08.05. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights | 347 | PR Newswire | - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular... ► Artikel lesen | |
| 27.03. | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights | 249 | PR Newswire | - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -
- TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk... ► Artikel lesen | |
| 10.01. | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) | 363 | PR Newswire | -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC-
-First patient expected to be dosed in SURF302 in Q2 2025-
... ► Artikel lesen | |
| 07.11.24 | Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights | 238 | PR Newswire | - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -
- IND cleared for Phase 2 study of TYRA-300 in pediatric... ► Artikel lesen | |
| 28.10.24 | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) | 239 | PR Newswire | - TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies -
- First child with achondroplasia expected to be dosed in Q1 2025... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,080 | 0,00 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| IMMUNOVANT | 16,075 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 56,29 | 0,00 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
| ARCUTIS BIOTHERAPEUTICS | 21,240 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,485 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| DISC MEDICINE | 70,28 | 0,00 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert | ||
| ARVINAS | 9,750 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,200 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,480 | 0,00 % | BofA Securities hebt Kursziel für Amylyx-Aktie auf 16 US-Dollar an | ||
| EVOTEC | 6,630 | -3,01 % | NetraMark Holdings, Evotec, Sartorius - Milliardengeschäfte im Blick! | Künstliche Intelligenz und Maschinelles Lernen sind mittlerweile in fast allen Branchen wichtige Schrittmacher. Wenn Pharmaunternehmen ein Medikament bis zur Marktreife entwickelt haben, sprudeln die... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 28,450 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| LENZ THERAPEUTICS | 48,600 | 0,00 % | Lenz Therapeutics platziert Aktienpaket im Wert von 80 Millionen US-Dollar | ||
| XENETIC BIOSCIENCES | 10,370 | 0,00 % | Xenetic Biosciences Stock Surges 123% | ||
| QIAGEN | 41,010 | +0,60 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| PRIME MEDICINE | 6,450 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 13,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.